Lipella pharmaceuticals unveils advanced bladder imaging technique at icicj conference

Lp-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer novel mri contrast agent, which received support from national institute of diabetes and digestive and kidney diseases 5 th international consultation on interstitial cystitis japan runs aug. 21-23 in kyoto pittsburgh, aug. 21, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo), a clinical-stage biotech company, will highlight clinical data on lp-20, a novel mri contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th international consultation on interstitial cystitis japan (icicj) in kyoto, japan, taking place august 21-23, 2024. lp-20, which has completed preclinical and proof-of-concept human trials, is administered via catheter into the bladder.
LIPO Ratings Summary
LIPO Quant Ranking